Tasipimidine (, ; developmental code names ODM-105 and ORM-19695), sold under the brand name Tessie, is an ñ<sub>2</sub>-adrenergic receptor agonist which is approved for the short-term treatment of fear and anxiety in dogs. It is also under development for the treatment of insomnia in humans. The drug is used as an oral solution in dogs, whereas its route of administration for humans is unspecified.
The drug acts as a potent and selective full agonist of the human ñ<sub>2A</sub>-adrenergic receptor. Conversely, it is a much weaker agonist of the rodent ñ<sub>2B</sub>-, ñ<sub>2C</sub>-, and ñ<sub>2D</sub>-adrenergic receptors. In addition, it shows only low affinity for ñ<sub>1</sub>-adrenergic receptors, where it appears to act as a partial agonist. Tasipimidine produces anxiolytic, sedative, hypolocomotor, hypotensive, and bradycardic effects in animals.
Tasipimidine is under development for use in humans by Orion Corporation. As of October 2024, it is in phase 2 clinical trials for this indication. The drug is or was also under development for the treatment of psychiatric disorders in humans, but no recent development for this indication has been reported. It has reached phase 1 trials for psychiatric disorders. Tasipimidine was approved for treatment of fear and anxiety in dogs in the European Union in 2021.